This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Uterine tubes and ligaments
CD2_BENIGN_UTERINE_TUBES_LIGAMENTS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleonly females |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D28
- Name in latin
- Neoplasma benignum alterius organi genitalis feminini specificati
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Uterine tubes and ligaments
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Uterine tubes and ligaments
- Benign neoplasm of other and unspecified female genital organs
- Benign neoplasm of other and unspecified female genital organs
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 222 | 222 | - |
| Unadjusted period prevalence (%) | 0.08 | 0.08 | - |
| Median age at first event (years) | 36.36 | 36.36 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 201
- Matched controls
- 2009
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
22101
ICD-8 Finland
Benign neoplasm of other female genital organs, Fallopian tube and broad ligament
+∞
118.8
102
*
2210A
ICD-9 Finland
Benign neoplasm of other female genital organs, Fallopian tube and uterine ligaments
+∞
60.5
55
*
D28.7
ICD-10 Finland
Benign neoplasm: Other specified female genital organs
+∞
38.8
36
*
115
Kela drug reimbursment
Breast cancer
+∞
16.9
16
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
86.5
14.8
16
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
13.7
13
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
11.6
11
*
L02BG04
ATC
letrozole; oral
46.0
11.0
13
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
10.5
10
*
130
Kela drug reimbursment
Malignant tumour
+∞
9.4
9
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
8.4
8
*
8204
FHL
Salpingo-oophorectomy
7.3
7.5
17
25
HAC20
NOMESCO Finland
Total mastectomy
+∞
7.3
7
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
7.3
7
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
7.3
7
*
L02BA01
ATC
tamoxifen; oral
+∞
7.3
7
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
72.0
6.5
7
*
PJA12
NOMESCO Finland
Sentinel node biopsy
72.0
6.5
7
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
7.4
6.3
14
20
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
11
21
5.46
5.58
1.1
1.2
—
—
—
0
0
27
102
2.88
5.48
3.7
1.4
6.1
2.7
ug/l
0.58
22
81
9
16
5.81
3.70
1.7
1.8
11.4
14.5
u/ml
—
9
16
59
382
1.74
3.12
2.0
2.0
—
—
—
0
0
104
786
1.61
3.02
3.3
3.5
—
—
—
0
0
42
263
1.74
2.47
5.8
4.9
33.4
33.9
%
0.15
31
150
14
62
2.34
2.12
1.9
1.6
—
—
—
0
0
5
142
0.34
1.96
1.2
1.7
—
—
—
0
0
106
864
1.43
1.90
4.0
4.4
1.2
1.2
mmol/l
0.45
89
756
13
59
2.28
1.88
2.1
1.6
—
—
—
0
0
116
989
1.36
1.48
8.8
5.8
3.9
4.1
e9/l
0.29
100
859
163
1477
1.39
1.35
4.6
4.4
12.0
13.2
mm/h
0.81
149
1346
9
43
2.14
1.32
3.3
2.3
—
—
—
0
0
5
19
2.67
1.22
1.0
1.8
1218.2
197.8
u/ml
—
5
19
34
243
1.47
1.19
17.4
23.8
1.5
1.3
inr
—
8
34
121
1061
1.31
1.18
4.2
3.7
6.6
6.7
mmol/l
0.25
111
976
88
740
1.31
1.16
3.9
3.6
27.0
69.6
ng/l
0.43
62
508
212
2041
1.86
1.11
11.1
8.9
24.7
23.3
u/l
0.62
203
1939
9
52
1.76
0.93
1.1
1.1
—
—
—
0
0
73
616
1.28
0.91
2.5
2.0
84.3
55.7
u/l
0.65
68
555
20
136
1.52
0.90
3.2
4.0
1.3
1.3
mmol/l
0.04
20
130
107
947
1.25
0.89
4.3
4.7
1.2
1.2
mmol/l
0.84
88
809
196
1877
1.38
0.78
14.9
12.1
16.6
20.6
mg/l
1.44
155
1430
26
193
1.39
0.77
4.3
4.3
102.9
103.6
mmol/l
0.38
26
187
154
1433
1.24
0.76
7.1
5.0
76.4
77.5
u/l
0.12
142
1297
161
1704
0.80
0.74
14.5
13.5
39.4
39.4
%
0.01
92
1141
41
501
0.78
0.73
3.8
2.9
0.2
0.5
e6/l
1.60
31
376
7
41
1.73
0.70
1.3
1.4
—
—
—
0
0
193
1851
1.33
0.69
6.3
6.1
39.5
40.1
mmol/mol
0.55
178
1704
5
30
1.68
0.62
1.8
1.6
39.6
66.1
%
—
5
21
109
994
1.19
0.61
3.9
3.9
0.0
0.0
estimate
0.00
14
168
15
106
1.45
0.59
2.2
1.6
—
—
—
0
0
206
2003
1.39
0.58
15.6
14.3
140.1
139.8
mmol/l
0.65
200
1941
25
316
0.76
0.58
4.1
2.5
1.0
1.5
e6/l
0.54
16
175
102
929
1.18
0.57
4.8
3.2
9.4
10.3
umol/l
0.82
95
859
31
380
0.79
0.57
3.5
4.1
119.5
86.2
ng/l
0.19
23
296
59
512
1.21
0.56
1.5
1.6
24.4
22.8
nmol/l
0.27
43
430
67
590
1.19
0.55
2.9
2.8
989.1
1211.5
ng/l
0.29
57
489
109
1001
1.17
0.55
4.9
5.4
0.0
0.0
estimate
0.00
12
161
12
83
1.47
0.53
3.8
4.3
27.0
25.8
mmol/l
0.29
12
83
201
1954
1.30
0.50
5.1
4.7
4.8
4.9
mmol/l
0.29
186
1781
206
2009
1.35
0.50
15.7
14.4
3.9
3.9
mmol/l
0.17
201
1943
109
1008
1.16
0.49
3.9
3.9
0.0
0.0
estimate
0.00
14
166
15
111
1.38
0.48
1.1
1.0
—
—
—
0
0
55
483
1.18
0.47
2.7
2.3
3.0
3.2
mg/l
0.21
49
406
98
902
1.15
0.46
2.3
2.3
85.6
80.9
nmol/l
0.94
87
789
58
515
1.17
0.43
4.2
4.3
0.1
0.0
estimate
0.47
14
169
70
631
1.16
0.43
3.0
2.0
106.8
142.7
u/l
1.30
65
591
6
92
0.64
0.43
1.5
1.7
—
—
—
0
0
52
459
1.17
0.42
4.7
4.3
1.0
1.0
kg/l
0.72
11
61
32
270
1.22
0.41
2.2
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
5
34
1.48
0.40
1.4
1.2
—
—
—
0
0
5
34
1.48
0.40
1.4
1.2
—
—
—
0
0
204
1995
1.28
0.40
5.6
5.4
2.8
2.8
mmol/l
0.08
186
1815
23
278
0.81
0.39
3.6
2.8
6.9
5.3
e6/l
0.18
15
139
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
9
66
1.38
0.39
2.8
1.8
—
—
—
0
0
83
764
1.14
0.38
3.9
4.1
—
—
—
0
0
5
76
0.65
0.36
1.0
1.3
3.3
4.0
g/l
—
5
59
52
576
0.87
0.34
1.7
1.6
1.2
1.3
mmol/l
0.55
43
486
186
1810
1.17
0.34
12.6
10.9
76.3
76.1
ml/min/173m2
0.05
156
1419
6
46
1.31
0.33
2.0
1.1
—
—
—
0
0
7
100
0.69
0.31
2.0
1.8
—
—
—
0
0
7
55
1.28
0.30
1.1
1.4
—
—
—
0
0
36
405
0.87
0.29
1.3
1.4
—
—
—
0
0
37
414
0.87
0.28
2.4
2.1
2.4
2.4
mmol/l
0.08
31
350
213
2101
1.34
0.28
22.3
18.2
131.9
132.3
g/l
0.16
208
2057
5
74
0.67
0.26
1.2
1.6
7.9
2.1
mg/l
—
5
53
31
274
1.15
0.26
7.1
7.1
—
—
—
0
0
22
189
1.18
0.25
4.7
5.3
2.4
1.9
mmol/l
0.12
16
152
37
410
0.88
0.25
1.3
1.3
39.9
38.2
iu/ml
0.04
12
145
189
1852
1.14
0.24
4.7
4.2
1.3
1.3
mmol/l
0.01
171
1657
5
38
1.32
0.23
1.4
1.5
—
—
—
0
0
11
88
1.26
0.23
1.5
2.1
1.1
1.1
%
0.19
11
88
7
92
0.75
0.23
1.9
1.3
—
—
—
0
0
5
41
1.22
0.22
1.6
1.4
—
—
—
0
0
8
101
0.78
0.21
20.8
3.0
5.8
4.5
pmol/l
—
8
80
8
103
0.77
0.21
1.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
5
43
1.17
0.21
1.4
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
11
90
1.23
0.19
1.7
1.4
—
—
—
0
0
205
2025
1.16
0.18
17.2
13.9
70.9
70.5
umol/l
0.12
205
2025
17
195
0.86
0.18
2.5
1.7
—
—
—
0
0
48
447
1.09
0.18
1.8
1.7
379.0
37677540.2
pmol/l
0.80
40
353
17
194
0.87
0.17
2.4
1.7
—
—
—
0
0
15
129
1.17
0.17
2.9
1.5
—
—
—
0
0
17
148
1.16
0.17
1.1
1.2
80.7
123.6
iu/ml
—
5
68
103
1068
0.93
0.17
2.9
2.6
—
—
—
0
0
6
76
0.78
0.16
1.0
1.3
—
—
—
0
0
87
836
1.07
0.15
3.2
2.7
100.5
88.5
ug/l
0.46
80
760
60
631
0.93
0.14
3.5
3.0
—
—
—
0
0
34
315
1.09
0.14
1.4
1.4
—
—
—
0
0
198
1957
1.11
0.14
5.4
4.8
5.8
5.9
mmol/l
1.40
182
1769
196
1938
1.10
0.12
5.3
4.7
1.6
1.6
mmol/l
1.09
180
1759
20
182
1.11
0.11
2.1
2.9
—
—
—
0
0
71
686
1.05
0.10
2.6
1.9
2.4
2.4
mmol/l
0.01
55
559
5
44
1.14
0.10
1.2
1.1
—
—
—
0
0
44
419
1.06
0.10
1.6
1.7
1257.1
1234.9
nmol/l
0.04
32
303
5
45
1.11
0.10
1.2
1.1
—
12.9
—
0
7
5
62
0.80
0.08
1.0
1.3
0.0
0.3
g/l
—
5
56
189
1873
1.06
0.08
6.5
5.4
14.9
1.9
mu/l
0.49
172
1699
6
72
0.83
0.07
1.8
1.8
—
—
—
0
0
6
75
0.79
0.07
1.5
1.2
—
—
—
0
0
6
75
0.79
0.07
1.5
1.2
—
—
—
0
0
38
397
0.95
0.07
1.3
1.3
17.2
12.3
u/ml
0.11
19
140
48
463
1.05
0.07
2.0
2.1
331.5
7409.0
umol/l
2.53
39
384
43
446
0.96
0.06
1.4
1.3
0.5
3.0
u/ml
—
8
120
42
407
1.04
0.05
1.5
1.6
1.0
1.0
mg/l
0.04
27
310
161
1622
0.97
0.03
5.7
4.4
14.8
14.8
pmol/l
0.11
144
1467
89
880
1.02
0.02
2.0
2.1
105.9
100.2
pmol/l
0.37
40
391
16
153
1.05
0.01
1.6
1.8
67.1
61.1
ml/min/173m2
—
10
57
18
187
0.96
0.01
2.1
1.8
4.1
5.2
umol/l
1.47
18
158
11
112
0.98
0.00
2.3
1.4
—
—
—
0
0
118
1175
1.01
0.00
3.0
2.7
63.0
47.5
u/l
0.46
108
1070
0
7
0.00
0.00
0.0
2.1
—
1.2
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
5
55
0.91
0.00
1.0
1.1
3.4
4.0
mmol/l
—
5
49
0
7
0.00
0.00
0.0
1.0
—
1585.1
—
0
7
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
8
80
1.00
0.00
5.4
5.0
26.6
25.0
mmol/l
—
8
73
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
6
61
0.98
0.00
1.2
1.2
386.3
474.3
mg/l
—
6
54
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
5
49
1.02
0.00
1.0
1.4
—
1.2
—
0
7
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
0.00
1.2
1.3
49.4
60.4
pmol/l
—
5
49
0
5
0.00
0.00
0.0
2.0
—
46.3
—
0
5
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
1.6
—
0
6
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
2.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_UTERINE_TUBES_LIGAMENTS_EXALLC – Benign neoplasm: Uterine tubes and ligaments
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).